Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
Sameek Roychowdhury(The Ohio State University Wexner Medical Center), Arul M. Chinnaiyan(University of Michigan), Moshe Talpaz(University of Michigan), Jeffrey W. Innis(University of Michigan), O. Alejandro Balbin(Novartis (United States)), Xuhong Cao(Howard Hughes Medical Institute), Nora M. Navone(The University of Texas MD Anderson Cancer Center), Jessica N. Everett(University of Michigan), Michael J. Quist(University of California, Los Angeles), Patricia Troncoso(The University of Texas MD Anderson Cancer Center), Lee Sam(University of Michigan), John C. Araujo(The University of Texas MD Anderson Cancer Center), Jens Rueter(Jackson Laboratory), Stephen B. Gruber(City Of Hope National Medical Center), Dan R. Robinson(University of Michigan), Kenneth J. Pienta(Johns Hopkins University), Shanker Kalyana‐Sundaram(University of Michigan), Scott Y. H. Kim(National Institutes of Health Clinical Center), Christopher D. Lao(University of Michigan), Terrence R. Barrette(University of Michigan), Yi-Mi Wu(University of Michigan), Matthew K. Iyer(University of Michigan), Lakshmi P. Kunju(University of Michigan), Robert J. Lonigro(University of Michigan), Javed Siddiqui(University of Michigan), David C. Smith(University of Michigan), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center)
Cited by 637
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k